首页> 中文期刊> 《英国医学杂志:中文版(BMJ)》 >钠-葡萄糖共转运蛋白-2抑制剂或胰高血糖素样肽-1受体激动剂治疗成人2型糖尿病:临床实践指南

钠-葡萄糖共转运蛋白-2抑制剂或胰高血糖素样肽-1受体激动剂治疗成人2型糖尿病:临床实践指南

摘要

临床问题对于存在不同心血管风险及肾脏结局的2型糖尿病患者,在原有生活方式干预和/或其他降糖药物的基础上加用钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂的获益及风险是什么?现行做法几十年来,2型糖尿病的治疗决策都以控制血糖为主导.SGLT-2抑制剂和GLP-1受体激动剂在传统观念中常被用于二甲双胍治疗后血糖仍控制不佳的患者.目前这一现状已经发生了改变,这得益于多项临床研究结果.研究显示SGLT-2抑制剂和GLP-1受体激动剂拥有独立于药物降糖作用之外的对于动脉粥样硬化性心血管病(CVD)和慢性肾脏病(CKD)的获益.

著录项

  • 来源
    《英国医学杂志:中文版(BMJ)》 |2021年第9期|523-531|共9页
  • 作者单位

    Chinese Evidence-based Medicine Center Cochrane China Center and MAGIC China Center West China Hospital Sichuan University Chengdu China;

    Department of Health Research Methods Evidence and Impact McMaster University Hamilton ON Canada;

    Department of Medicine McMaster University Hamilton ON Canada;

    Newbridge Surgery Bath UK;

    Sydney School of Public Health The University of Sydney Sydney Australia;

    Centre for Kidney Research The Children's Hospital at Westmead Sydney Australia;

    Renal Division Ghent University Hospital Belgium;

    University of California Davis USA;

    Department of Endocrinology Clinic of Medicine St Olavs Hospital Trondheim University Hospital Trondheim Norway;

    K.G.Jebsen Center for Genetic Epidemiology Department of Public Health and Nursing NTNU Norwegian University of Science and Technology Trondheim Norway;

    The George Institute for Global Health UNSW India;

    Prasanna School of Public Health Manipal Academy of Higher Education Manipal India;

    Department of Public Health and Primary Care KU Leuven Leuven Belgium;

    Service of Endocrinology Diabetes Nutrition and Patient Therapeutic Education Geneva University Hospitals Geneva Switzerland;

    International Medical Center/Ward of General Practice West China Hospital Sichuan University Chengdu China;

    University of Oslo Oslo Norway;

    MAGIC Evidence Ecosystem Foundation;

    Founder & CEHD iAdvocate Inc. Virginia Patient partner;

    Chinese Evidence-based Medicine Center Cochrane China Center and MAGIC China Center West China Hospital Sichuan University Chengdu China;

    Department of Health Research Methods Evidence and Impact McMaster University Hamilton ON Canada;

    The Center of Gerontology and Geriatrics/ National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu China;

    Department of Health Research Methods Evidence and Impact McMaster University Hamilton ON Canada;

    Department of Internal Medicine Division of Nephrology and Hypertension University of Kansas Kansas City USA;

    苏州大学附属第二医院内分泌科;

    Department of Health Research Methods Evidence and Impact McMaster University Hamilton ON Canada;

    Department of Health Research Methods Evidence and Impact McMaster University Hamilton ON Canada;

    Department of Medicine McMaster University Hamilton ON Canada;

    Department of Medicine University of Otago Christchurch New Zealand;

    Plataforma INVEST Medicina UANL-KER Unit (KER Unit México) Subdirección de Investigación Universidad Autónoma de Nuevo León Monterrey 64460 México;

    Knowledge and Evaluation Research Unit in Endocrinology Mayo Clinic Rochester MN 55905 USA;

    Endocrinology Division Department of Internal Medicine University Hospital "Dr.José E.González "Universidad Autónoma de Nuevo León Monterrey 64460 México;

    Ted Rogers Center for Heart Research Canada;

    Service of Endocrinology Diabetes Nutrition and Patient Therapeutic Education Geneva University Hospitals Geneva Switzerland;

    Department of Health Research Methods Evidence and Impact McMaster University Hamilton ON Canada;

    Department of Medicine McMaster University Hamilton ON Canada;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类
  • 关键词

相似文献

  • 中文文献
  • 外文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号